AEON Biopharma, Inc. (AEON)
NYSE American · Healthcare · Biotechnology
$0.27−3.23%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.5M
- 52-week range
- $0.177 – $1.45
- 52-week change
- −70.16%
- EPS (trailing)
- −$4.39
- Analyst rating
- 1.3 Strong buy
Fiscal year to Dec 2025
- Net income
- −$39.2M
- Diluted EPS
- −$3.95
- Free cash flow
- −$17.3M
From the company’s annual report on SEC EDGAR.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Headquarters: Irvine, United States · 8 employees · aeonbiopharma.com